Patents by Inventor Nancy Maizel
Nancy Maizel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9815885Abstract: The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of B cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity. The diversification process can be modulated, accelerated, halted, switched between methods of mutagenesis and the like. The modulation of diversification in accordance with the invention is both inducible and reversible. The invention provides a means of rapid and feasible development of a repertoire of variant immunoglobulins and other polypeptides.Type: GrantFiled: December 23, 2015Date of Patent: November 14, 2017Assignee: UNIVERSITY OF WASHINGTONInventors: Nancy Maizels, W. Jason Cummings, Munehisa Yabuki
-
Patent number: 9777065Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.Type: GrantFiled: July 1, 2015Date of Patent: October 3, 2017Assignee: Omeros CorporationInventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
-
Publication number: 20170166875Abstract: The technology described herein is directed to engineered endonucleases whose activity is restricted to certain phases of the cell cycle. Provided herein are compositions and methods relating to such engineered endonucleases.Type: ApplicationFiled: December 13, 2016Publication date: June 15, 2017Applicant: UNIVERSITY OF WASHINGTONInventors: Nancy Maizels, Luther Davis, Charlotte A. James, Yinbo Zhang
-
Patent number: 9677070Abstract: The disclosure relates generally to the targeting of genes to, and their integration into, an immunoglobulin (antibody) heavy chain locus. In particular, the methods described herein contemplate replacing the single rearranged heavy chain V, D, and J genes of a B cell lymphoma such as DT40 with independently rearranged VH-D-JH genes of chicken, in a system for generating immunoglobulin diversity. Also contemplated is replacement of the chicken VH-D-JH with rearranged VH-D-JH genes of other vertebrates including human in a system for generating immunoglobulin diversity, with the exception of any substitution disclosed and claimed in PCT application WO 2009/029315 A2. Also described is construction of a diverse chicken immunoglobulin heavy chain VDJ library in DT40 by homologous gene replacement of the single endogenous rearranged VDJ gene with a chicken VDJ repertoire using the described targeting vectors.Type: GrantFiled: March 13, 2013Date of Patent: June 13, 2017Assignees: Omeros Corporation, University of Washington Through Its Center for CommercializationInventors: Daniel S. Allison, W. Jason Cummings, John B. Leppard, Nancy Maizels, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
-
Publication number: 20160369258Abstract: The present invention relates generally to mutagenesis of target genes that enhances the natural mutagenic capabilities of adaptive immune cells by providing a chimeric construct that exploits the ability of molecules such as AID to stimulate diversification and the ability of a second molecule to restrict nuclear activity of the molecules and/or protect cell viability. The invention provides a method for stimulating diversification in expressed genes, such as antibody genes, using polypeptides whose nuclear activity is restricted to specific phases of the cell cycle. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity, or for developing T cells for immunotherapy. The invention provides an improved means of developing a repertoire of variant immunoglobulins and other polypeptides.Type: ApplicationFiled: March 11, 2015Publication date: December 22, 2016Applicant: UNIVERSITY OF WASHINGTONInventors: Nancy Maizels, Quy Le
-
Publication number: 20160333107Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.Type: ApplicationFiled: July 1, 2015Publication date: November 17, 2016Inventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
-
Publication number: 20160201053Abstract: The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of B cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity. The diversification process can be modulated, accelerated, halted, switched between methods of mutagenesis and the like. The modulation of diversification in accordance with the invention is both inducible and reversible. The invention provides a means of rapid and feasible development of a repertoire of variant immunoglobulins and other polypeptides.Type: ApplicationFiled: December 23, 2015Publication date: July 14, 2016Applicant: UNIVERSITY OF WASHINGTONInventors: Nancy Maizels, W. Jason Cummings, Munehisa Yabuki
-
Patent number: 9346888Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.Type: GrantFiled: November 14, 2013Date of Patent: May 24, 2016Assignee: Omeros CorporationInventors: John Benjamin Leppard, Christi L. Wood, W. Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
-
Patent number: 9273119Abstract: The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of B cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity. The diversification process can be modulated, accelerated, halted, switched between methods of mutagenesis and the like. The modulation of diversification in accordance with the invention is both inducible and reversible. The invention provides a means of rapid and feasible development of a repertoire of variant immunoglobulins and other polypeptides.Type: GrantFiled: February 5, 2014Date of Patent: March 1, 2016Assignee: UNIVERSITY OF WASHINGTONInventors: Nancy Maizels, W. Jason Cummings, Munehisa Yabuki
-
Publication number: 20160040155Abstract: The technology described herein is directed to methods for modulating the rate of homology-directed repair, e.g. in methods for gene modification.Type: ApplicationFiled: April 16, 2014Publication date: February 11, 2016Inventors: Nancy MAIZELS, Luther DAVIS
-
Publication number: 20150376645Abstract: In some embodiments the present disclosure provides a composition for targeted alteration of a DNA sequence and methods of altering the targeted DNA sequence using the composition. In some embodiments such a composition comprises a MiniVector comprising a nucleic acid sequence template for homology-directed repair, alteration, or replacement of the targeted DNA sequence within a cell in vivo or in vitro, where the MiniVector lacks both a bacterial origin of replication and an antibiotic selection gene, and wherein the Mini Vector has a size up to about 2,500 base pairs.Type: ApplicationFiled: May 30, 2013Publication date: December 31, 2015Applicants: BAYLOR COLLEGE OF MEDICINE, UNIVERSITY OF WASHINGTON CENTER FOR COMMERCIALIZATIONInventors: E. Lynn Zechiedrich, Jonathan Fogg, Daniel James Catanese, JR., Nancy Maizel, Olivier Humbert
-
Publication number: 20150322134Abstract: The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of B cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity. The diversification process can be modulated, accelerated, halted, switched between methods of mutagenesis and the like. The modulation of diversification in accordance with the invention is both inducible and reversible. The invention provides a means of rapid and feasible development of a repertoire of variant immunoglobulins and other polypeptides.Type: ApplicationFiled: February 5, 2014Publication date: November 12, 2015Applicant: University of WashingtonInventors: Nancy Maizels, W. Jason Cummings, Munehisa Yabuki
-
Patent number: 9102724Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.Type: GrantFiled: August 9, 2012Date of Patent: August 11, 2015Assignee: Omeros CorporationInventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
-
Publication number: 20140178385Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.Type: ApplicationFiled: November 14, 2013Publication date: June 26, 2014Applicant: Omeros CorporationInventors: John Benjamin Leppard, Christi L. Wood, W. Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
-
Patent number: 8679845Abstract: The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of B cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity. The diversification process can be modulated, accelerated, halted, switched between methods of mutagenesis and the like. The modulation of diversification in accordance with the invention is both inducible and reversible. The invention provides a means of rapid and feasible development of a repertoire of variant immunoglobulins and other polypeptides.Type: GrantFiled: June 2, 2008Date of Patent: March 25, 2014Assignee: University of WashingtonInventors: Nancy Maizels, W. Jason Cummings, Munehisa Yabuki
-
Publication number: 20140056868Abstract: In some embodiments the present disclosure provides a composition for targeted alteration of a DNA sequence and methods of altering the targeted DNA sequence using the composition. In some embodiments such a composition comprises a MiniVector comprising a nucleic acid sequence template for homology-directed repair, alteration, or replacement of the targeted DNA sequence within a cell in vivo or in vitro, where the MiniVector lacks both a bacterial origin of replication and an antibiotic selection gene, and wherein the MiniVector has a size up to about 2,500 base pairs.Type: ApplicationFiled: May 30, 2013Publication date: February 27, 2014Applicants: University of Washington Center for Commercialization, Baylor College of MedicineInventors: Lynn E. Zechiedrich, Jonathan Fogg, Daniel James Catanese, JR., Erol Bakkalbasi, Nancy Maizel, Olivier Humbert
-
Patent number: 8609818Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.Type: GrantFiled: March 9, 2012Date of Patent: December 17, 2013Assignee: Omeros CorporationInventors: John Benjamin Leppard, Christi L Wood, W Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S Allison, Larry W Tjoelker
-
Publication number: 20130261012Abstract: The disclosure relates generally to the targeting of genes to, and their integration into, an immunoglobulin (antibody) heavy chain locus. In particular, the methods described herein contemplate replacing the single rearranged heavy chain V, D, and J genes of a B cell lymphoma such as DT40 with independently rearranged VH-D-JH genes of chicken, in a system for generating immunoglobulin diversity. Also contemplated is replacement of the chicken VH-D-JH with rearranged VH-D-JH genes of other vertebrates including human in a system for generating immunoglobulin diversity, with the exception of any substitution disclosed and claimed in PCT application WO 2009/029315 A2. Also described is construction of a diverse chicken immunoglobulin heavy chain VDJ library in DT40 by homologous gene replacement of the single endogenous rearranged VDJ gene with a chicken VDJ repertoire using the described targeting vectors.Type: ApplicationFiled: March 13, 2013Publication date: October 3, 2013Applicants: University of Washington Through Its Center for Commercialization, OMEROS CORPORATIONInventors: Daniel S. Allison, W. Jason Cummings, John B. Leppard, Nancy Maizels, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
-
Publication number: 20130095104Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.Type: ApplicationFiled: August 9, 2012Publication date: April 18, 2013Inventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
-
Publication number: 20120258121Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.Type: ApplicationFiled: March 9, 2012Publication date: October 11, 2012Applicant: Omeros CorporationInventors: John Benjamin Leppard, Christi L. Wood, W. Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker